STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Companies Mid-Cap

Chewy’s Q2 FY24 Results: A Turnaround in Active Customer Growth and Optimistic FY24 Outlook

byLuca Blaumann
August 29, 2024
in Mid-Cap, Retail
Reading Time: 5 mins read
Share on TwitterShare on LinkedIn

Chewy Beats Earnings Expectations, Raises Guidance Amid Strong Margins and Stabilizing Market Conditions

Chewy (CHWY), the leading online retailer of pet products, delivered a strong performance in its second quarter of fiscal year 2024, beating expectations on the bottom line and raising its full-year guidance. The company’s ability to grow its active customer base for the first time in over a year, coupled with robust margins and a conservative yet optimistic outlook, marks a potential turning point for the e-commerce giant in a challenging market environment.

Solid Q2 Performance: A Mix of Growth and Stability

In Q2 FY24, Chewy reported revenue of $2.86 billion, marking a 2.6% year-over-year increase. This figure aligned with the high end of the company’s guided range of $2.84-$2.86 billion and met consensus expectations. However, the standout performance came from Chewy’s bottom line, where it sharply beat expectations with an adjusted EBITDA of $145 million, or 5.1% of sales, far surpassing the consensus estimate of $111 million (3.9%).

One of the most significant developments in this quarter was the growth in Chewy’s active customer base. The company reported 20 million active customers, slightly above the consensus forecast of 19.97 million and better than Chewy’s internal estimate of 19.93 million. This marks the first time in over a year that Chewy has grown its active customer count, a key performance indicator (KPI) that had previously been under pressure. The increase was driven by stronger-than-expected new customer acquisitions and an accelerated pace of customer reactivation, fueled by Chewy’s enhanced Customer Relationship Management (CRM) strategies and targeted marketing initiatives.

Net sales per active customer (NSPAC) came in at $565, slightly below the consensus of $567 but still representing a record high for the company. Despite the ongoing disinflation in pet food prices, Chewy managed to increase spending per customer, thanks to its successful wallet share initiatives, which encouraged customers to spend more across a broader range of products.

Chewy’s gross margins also outperformed expectations, reaching 29.5%, up 120 basis points year-over-year and above the consensus estimate of 28.9%. This margin strength was largely driven by the company’s high-margin sponsored ads program and a higher mix of healthcare product sales. Additionally, Chewy demonstrated impressive cost control, with Selling, General & Administrative (SG&A) expenses accounting for 18.8% of sales, better than the consensus estimate of 19.2%. This efficiency was supported by disciplined corporate payroll management and gains from the company’s automated distribution centers.

Raised FY24 Guidance: Conservative Yet Encouraging

Following its strong Q2 results, Chewy raised its full-year FY24 guidance, reflecting continued confidence in its business model. The company now expects full-year revenue in the range of $11.6-$11.8 billion, maintaining its previous outlook but implying slightly lower sales growth in the second half of FY24 compared to consensus expectations. However, the company also raised its adjusted EBITDA margin guidance to 4.5-4.7%, up from the prior range of 4.1-4.3%, indicating stronger profitability in the face of softer sales growth.

For Q3 FY24, Chewy guided revenue between $2.84 billion and $2.86 billion, representing a year-over-year growth of 3.4% to 4.2%. While this guidance is slightly below the consensus midpoint of $2.86 billion, it reflects Chewy’s conservative approach, particularly in light of the ongoing economic uncertainty and fluctuating consumer demand.

Chewy’s ability to maintain flat year-over-year active customer numbers by the end of FY24, despite exceeding expectations in the first half, further underscores the company’s cautious outlook. The company is aware of the challenges posed by the elevated retention headwinds from its first half of FY23 cohorts, which had a higher mix of discount-driven customers, potentially pressuring churn rates.

Market Trends and Competitive Landscape

Chewy’s Q2 performance and guidance offer positive read-throughs for the broader pet industry. The company continues to gain market share and expand its margins despite operating in a soft industry environment. Chewy reported encouraging trends in pet household formation, with net adoptions up in the low teens year-over-year and relinquishments down in the low to mid-single digits. These trends, coupled with the stabilization of discretionary demand and promotional activity, are encouraging signs for the pet retail market.

The company’s growth in sponsored ads and high-margin pharmacy product sales are expected to continue driving margin expansion into the second half of FY24. Sponsored ads contributed materially to Q2 and Q1 margin strength, and the program is on track to reach approximately 1% of sales in FY24. Additionally, Chewy’s improved fulfillment network, which contributed about 20 basis points to SG&A leverage in Q2, is poised to deliver further benefits as volumes potentially accelerate in the second half.

Outlook for FY24 and Beyond

Looking ahead, Chewy’s FY24 outlook appears conservative but achievable, with potential upside if industry demand remains stable or improves. The company’s strategic initiatives, including the growth of its sponsored ads program, cross-sales of high-margin products, and disciplined cost management, position it well for continued margin expansion.

Beyond FY24, Chewy is expected to return to mid-single-digit to high-single-digit revenue growth, with sustained margin improvement driven by the favorable mix of high-margin products and services. However, SG&A leverage may be limited as the company reinvests in growth initiatives.

One potential near-term challenge for Chewy’s stock is the possibility of additional stock sales by private equity owner BC Partners, which could cap share price appreciation. However, the company’s long-term fundamentals remain strong, and analysts continue to rate Chewy as an “Outperform” with a target price of $35.

Chewy’s Q2 FY24 results mark a positive turning point for the company, with growth in active customers, strong margins, and an optimistic outlook for the remainder of the year. While the guidance remains conservative, the company’s strategic initiatives and disciplined execution provide a solid foundation for future growth. As Chewy navigates the competitive landscape and evolving market conditions, its ability to capitalize on high-margin opportunities and maintain customer engagement will be key to sustaining its upward trajectory.

You might like this article:Affirm’s Solid Q4 Performance and Optimistic FY25 Guidance: A Mixed Outlook Amidst Fierce Competition

Tags: BreakingEarningsGrowthMoversNewsStock Market
Previous Post

Affirm’s Solid Q4 Performance and Optimistic FY25 Guidance: A Mixed Outlook Amidst Fierce Competition

Next Post

Eos Energy Enterprises Secures $30 Million Milestone, Paving the Way for Growth in Long-Duration Energy Storage

Related Posts

Viking Therapeutics Moves Oral Obesity Drug Into Late-Stage Development

byLuca Blaumann
February 11, 2026
0

Company advances VKTX program as competition intensifies in the rapidly expanding weight-loss market Viking Therapeutics (VKTX) announced Wednesday that it...

trading-chart

Dentsply Sirona’s $45 Bull Case: A Turnaround Leveraged to a Dental Recovery

byLuca Blaumann
February 6, 2026
0

If demand stabilizes, cost savings stick, and digital/aligners re-accelerate, XRAY could re-rate sharply Dentsply Sirona (XRAY) has been treated like...

KULR Technology: The Market Trades Bitcoin — I’m Watching the Battery Business

byLiliana Vida
February 3, 2026
0

The big picture Over the past year, KULR’s stock has behaved more like a Bitcoin proxy than a niche industrial...

Next Post
warner bros discovery

Eos Energy Enterprises Secures $30 Million Milestone, Paving the Way for Growth in Long-Duration Energy Storage

Latest News

Viking Therapeutics Moves Oral Obesity Drug Into Late-Stage Development

Banks Push Back on Stablecoin Yields, Freezing Key Crypto Bill in Congress

Ancora Capital Challenges Netflix Deal for Warner Bros. Discovery

Robinhood Shares Slide After Revenue Miss Dampens Record Year

Ford Posts Heavy Losses as EV Charges and Warranty Costs Weigh on Results

Based on Your Interest

Blog

Coca-Cola Shares Slip as Management Strikes a Cautious Tone for 2026

February 10, 2026
Blog

Why KULR Could Be a Quiet Enabler of Space-Based Solar Power (SBSP) Over the Long Term

February 10, 2026
drugs-2
Blog

FDA Flags Novo Nordisk’s Wegovy Pill Ad for Misleading Claims

February 9, 2026

Recommended

Blog

Oracle Rebounds as Big Tech’s AI Spending Revives Software Optimism

February 9, 2026
Biotechnology

Hims & Hers Shares Plunge as FDA Tightens Grip on Compounded GLP-1 Drugs

February 9, 2026
Auto Manufacturers

Stellantis Takes $26 Billion EV Write-Down as Electrification Strategy Resets

February 6, 2026
Mid-Cap

Dentsply Sirona’s $45 Bull Case: A Turnaround Leveraged to a Dental Recovery

February 6, 2026
Entertainment

Reddit Enters a New Growth Era as Profits Surge and Share Buyback Signals Confidence

February 5, 2026
Stoxpo

Follow us on social media:

Highlights

  • Viking Therapeutics Moves Oral Obesity Drug Into Late-Stage Development
  • Banks Push Back on Stablecoin Yields, Freezing Key Crypto Bill in Congress
  • Ancora Capital Challenges Netflix Deal for Warner Bros. Discovery
  • Robinhood Shares Slide After Revenue Miss Dampens Record Year
  • Ford Posts Heavy Losses as EV Charges and Warranty Costs Weigh on Results

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

Viking Therapeutics Moves Oral Obesity Drug Into Late-Stage Development

February 11, 2026

Banks Push Back on Stablecoin Yields, Freezing Key Crypto Bill in Congress

February 11, 2026

Ancora Capital Challenges Netflix Deal for Warner Bros. Discovery

February 11, 2026
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.